Respiratory Infection (for Example, Pneumonia, Bronchitis)SCORE-PedsNCT07334795
Intermountain Stewardship in Community Outpatient Settings-Resources & Engagement-Pediatrics
An observational study of Respiratory Infection (for Example, Pneumonia, Bronchitis) and Antibiotic, run by Intermountain Health Care, Inc. at 1 site in United States.
Trial summary
The goal of this implementation project is to detail the process of implementing the best practice of antibiotic stewardship in the pediatric population across the Intermountain Health medical system. Read more about this study
- Who is it for?
- Ages 6 months to 17 years
- Conditions the study is for
- Respiratory Infection (for Example, Pneumonia, Bronchitis), Antibiotic, Antibiotic Duration
- What is being tested?
- Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation
- How many people
- 259,000 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jan 2026to 15 Jan 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: All children meeting eligibility criteria and treated at any facility within the Intermountain region specified (wave 1 \& wave 2) between January 1, 2026 and December 31, 2028.
Who may be able to join
- Age 6 months through 17 years
- ARTI diagnosis (acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP))
Who cannot join
- Age <6months or >18 years
- No ARTI diagnosis
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this implementation project is to detail the process of implementing the best practice of antibiotic stewardship in the pediatric population across the Intermountain Health medical system. The main questions it aims to answer are:
- How can a large healthcare system drive high adherence to antibiotic stewardship across a large and diverse number of sites?
- How do determinants of implementation and needed strategies vary by context?
- What is the utility of a higher-resource implementation effort (named "Boost) focusing on outlier sites?
Data will be collected on number of children reached, adherence changes over time, types of implementation strategies employed, and characteristics of sites, prescribers, and patients.
- Conditions
- Respiratory Infection (for Example, Pneumonia, Bronchitis), Antibiotic, Antibiotic Duration, Antibiotic Prescribing for Acute Respiratory-tract Infections
- Being tested
- Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation
- Medical subject headings
- Respiratory Tract Infections, Pneumonia, Bronchitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitationOther
- facilitate improved adherence to guideline-based prescribing, we plan a variety of implementation strategies to be employed in tandem including training \& education, EMR tools (e.g., Smart sets, express lanes, preference lists), audit and feedback reports and dashboards, and facilitation.
| Study group | Role | What they receive |
|---|---|---|
| Children with ARTIs, Wave 1 | Children under 18 treated in Wave 1 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP) Receives: Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation | |
| Children with ARTIs, Wave 2 | Children under 18 treated in Wave 2 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP) Receives: Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Guideline-adherent Broad vs. Narrow Spectrum Antibiotic Prescribing
Rates of narrow-spectrum antibiotic (AB) prescriptions as a proportion of all antibiotics prescribed in aggregate and within each of these diagnoses: Acute otitis media, Group A streptococcal pharyngitis, Acute sinusitis, and Pneumonia.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Guideline-adherent Duration of Antimicrobial Therapy
Rate of AB prescriptions with guideline-adherent number of days prescribed as proportion of all AB prescriptions in aggregate and for each of the target ARTI diagnoses.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Secondary outcomes (3)
Rate of Treatment Failure
Clinical encounter for the same diagnosis between 2 and 14 days following the index encounter and receipt of an alternative antibiotic for the same respiratory diagnosis during the return visit.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Staff): Adherence to Protocols
Number and proportion of prescribers who are "adherent" to guideline-based prescribing protocols for Broad vs. Narrow Spectrum AB Prescribing, and Duration.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Organization): Adherence to Protocols
Number and proportion of sites where 60% of prescribers are adherent.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start15 Jan 2026
- Primary completion15 Jan 2029 (estimated)
- Study completion15 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Respiratory Infection (for Example, Pneumonia, Bronchitis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 259,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Intermountain Health Care, Inc.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07334795
- Sponsor's protocol ID
- HSII_IHC_IMP-PS2
- Acronym
- SCORE-Peds
- Status last verified
- Oct 2025
- First submitted
- 31 Dec 2025
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is an implementation study using observational data with a waiver of consent. Therefore, there is no consent to allow for the sharing of IPD.
Publications
Fowles TR, Patel PK, Seibert AM, Hersh AL, Belnap T, Hanna B, Szymczak JE, Keenan HT, Barney BJ, Srivastava R. Implementation of a pediatric antibiotic stewardship intervention across a large integrated health system: protocol to optimize antibiotic selection and prescription duration for acute respiratory tract infections in children. Implement Sci Commun. 2026 Apr 9;7(1):93. doi: 10.1186/s43058-026-00915-0.
PubMed 41952161
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intermountain Stewardship in Community Outpatient Settings-Resources & Engagement-Pediatrics
- ClinicalTrials.gov ID
- NCT07334795
- Acronym / sponsor ID
- SCORE-Peds / HSII_IHC_IMP-PS2
- Conditions
- Respiratory Infection (for Example, Pneumonia, Bronchitis), Antibiotic, Antibiotic Duration, Antibiotic Prescribing for Acute Respiratory-tract Infections
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 259,000 participants (estimated)
- Lead sponsor
- Intermountain Health Care, Inc.University, hospital or other
- Study start
- 15 Jan 2026 (actual)
- Primary completion
- 15 Jan 2029 (estimated)
- Study completion
- 15 Jan 2029 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this implementation project is to detail the process of implementing the best practice of antibiotic stewardship in the pediatric population across the Intermountain Health medical system. The main questions it aims to answer are:
- How can a large healthcare system drive high adherence to antibiotic stewardship across a large and diverse number of sites?
- How do determinants of implementation and needed strategies vary by context?
- What is the utility of a higher-resource implementation effort (named "Boost) focusing on outlier sites?
Data will be collected on number of children reached, adherence changes over time, types of implementation strategies employed, and characteristics of sites, prescribers, and patients.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Children with ARTIs, Wave 1 | – | Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitationChildren under 18 treated in Wave 1 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP) |
| Children with ARTIs, Wave 2 | – | Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitationChildren under 18 treated in Wave 2 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP) |
Who may qualify
- Ages
- 6 months to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- All children meeting eligibility criteria and treated at any facility within the Intermountain region specified (wave 1 \& wave 2) between January 1, 2026 and December 31, 2028.
Key inclusion criteria (2 listed)
- Age 6 months through 17 years
- ARTI diagnosis (acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP))
Key exclusion criteria (2 listed)
- Age <6months or >18 years
- No ARTI diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitationo facilitate improved adherence to guideline-based prescribing, we plan a variety of implementation strategies to be employed in tandem including training \& education, EMR tools (e.g., Smart sets, express lanes, preference lists), audit and feedback reports and dashboards, and facilitation. | Other | Children with ARTIs, Wave 1, Children with ARTIs, Wave 2 |
Primary outcome
Guideline-adherent Broad vs. Narrow Spectrum Antibiotic Prescribing
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Rates of narrow-spectrum antibiotic (AB) prescriptions as a proportion of all antibiotics prescribed in aggregate and within each of these diagnoses: Acute otitis media, Group A streptococcal pharyngitis, Acute sinusitis, and Pneumonia.
Guideline-adherent Duration of Antimicrobial Therapy
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Rate of AB prescriptions with guideline-adherent number of days prescribed as proportion of all AB prescriptions in aggregate and for each of the target ARTI diagnoses.
3 secondary outcomes
Rate of Treatment Failure
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Staff): Adherence to Protocols
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Organization): Adherence to Protocols
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
- Derived from this study: PubMed 41952161Fowles TR, Patel PK, Seibert AM, Hersh AL, Belnap T, Hanna B, Szymczak JE, Keenan HT, Barney BJ, Srivastava R. Implementation of a pediatric antibiotic stewardship intervention across a large integrated health system: protocol to optimize antibiotic selection and prescription duration for acute respiratory tract infections in children. Implement Sci Commun. 2026 Apr 9;7(1):93. doi: 10.1186/s43058-026-00915-0.
- Individual participant dataSharing planned: No. This is an implementation study using observational data with a waiver of consent. Therefore, there is no consent to allow for the sharing of IPD.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Respiratory Infection (for Example, Pneumonia, Bronchitis) and Antibiotic, run by Intermountain Health Care, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Guideline-adherent Broad vs. Narrow Spectrum Antibiotic Prescribing (time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07334795, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.